What Lucid Psycheceuticals does

Lucid Psycheceuticals Inc. is a Toronto-based, pre-revenue specialty biopharmaceutical company founded in 2020 that develops small molecule drugs inspired by the mechanisms of action of psychedelics. The company targets three therapeutic areas — mental health disorders (including major depressive disorder), neurodegenerative disorders (Alzheimer's, Parkinson's, multiple sclerosis and related prodromal conditions), and inflammatory/immunology disorders — with a stated mission of pursuing 'total brain health.' Its lead candidate, Lucid-201, is a known molecule with clinical proof of efficacy in MDD that has been short-listed for further development by the Lucid team. The company's pipeline includes additional new chemical entities (NCEs) acquired through an exclusive worldwide license from University Health Network (UHN) in Toronto in May 2021, along with associated patents and preclinical efficacy data. The scientific approach emphasizes novel small molecule therapeutics aimed at preventing or potentially reversing neurodegeneration, distinguishing it from first-generation psychedelic-assisted therapy models.

The company is a wholly-owned subsidiary of FSD Pharma Inc. (NASDAQ: HUGE, CSE: HUGE, FRA: 0K9), a publicly-traded biopharmaceutical company, which provides corporate structure and financial backing. Lucid operates with 1-10 employees, is headquartered at 243 College Street, Suite 101, Toronto, and is led by founder and CEO Lakshmi Kotra. It pursues standard FDA and Health Canada regulatory pathways for its drug candidates and is actively recruiting across scientific, regulatory, IP, and business development functions.

Lucid's business model is a traditional pre-commercial pharmaceutical development model: the company is pre-revenue, generates no product sales, and expects any future revenue to come from commercialization of approved drugs through pharmaceutical sales channels or potential out-licensing deals. There are no current customers, no commercial pricing, and no active distribution channels. Customer segments are defined by future end-use cases — patients with MDD, neurodegenerative disease, and inflammatory disorders — rather than paying B2B clients. Marketing today is limited to a corporate website, LinkedIn, and Twitter presence aimed at investors, partners, and prospective talent.

Name

Lucid Psycheceuticals

Legal name

Lucid Psycheceuticals Inc.

Website

https://lucidpsycheceuticals.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Lucid Psycheceuticals is a Toronto-based, pre-revenue biopharmaceutical company developing psychedelics-inspired small molecule drugs for mental health, neurodegenerative, and inflammatory disorders, and operates as a wholly-owned subsidiary of FSD Pharma Inc.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

Keywords

• Psychedelic pharmaceutical development
• Small molecule therapeutics
• Neurodegenerative disorder treatments
• Mental health drug discovery
• Inflammatory disorder drugs

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Drug Sales: Pre-revenue biotech company. Future revenue expected from commercialization of novel therapeutic drugs following successful clinical development and regulatory approval. Revenue model will likely involve direct pharmaceutical product sales.

Go-to-market motion1 record

Marketing channels3 records

Core offering

Lucid Psycheceuticals is a pre-revenue specialty psychedelic pharmaceutical company developing small molecule drugs inspired by the mechanisms of action of psychedelics. The company is advancing three drug pipelines targeting mental health disorders (led by Lucid-201 for major depressive disorder), neurodegenerative disorders (such as Alzheimer's, Parkinson's, and multiple sclerosis), and inflammatory disorders, with its core intellectual property consisting of an exclusive worldwide license to new chemical entities (NCEs) from University Health Network in Toronto, Canada.

Product overview

Lucid Psycheceuticals is a psychedelics-inspired biotech company developing novel small molecule drugs for neuro and inflammatory disorders. The company has a pipeline of molecules targeting mental health disorders (including Lucid-201 for major depressive disorder), neurodegenerative disorders, and inflammatory disorders. In May 2021, Lucid acquired an exclusive worldwide license to new chemical entities (NCEs), associated patents, and preclinical efficacy data from University Health Network (UHN) in Toronto, Canada. The company operates as a wholly-owned subsidiary of FSD Pharma Inc.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Clinical proof of efficacy demonstrated for Lucid-201 in major depressive disorder (MDD)

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• University Health Network (UHN)coreStrategic or Co-development Partner · 1 May 2021Lucid completed the acquisition of exclusive worldwide license to new chemical entities (NCEs), associated patents and preclinical efficacy data from University Health Network (UHN) in Toronto, Canada. This partnership provides the company with its core IP portfolio and foundational technology for drug development.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Compass Pathways: Public clinical-stage mental health company developing psilocybin-based therapies for treatment-resistant depression. Directly comparable to Lucid as a psychedelic-inspired CNS therapeutics developer targeting MDD-related indications.
• MindMed: Public psychedelic-inspired biotech developing novel therapeutics for mental health and addiction. Closely comparable to Lucid's psychedelic-inspired small-molecule approach in CNS indications.
• Atai Life Sciences: Public clinical-stage biopharmaceutical company developing psychedelic and complementary therapies for mental health. Comparable platform approach and indication overlap with Lucid.
• Cybin: Public psychedelic therapeutics company developing deuterated psilocybin analogs and other psychedelic-inspired molecules for depression and CNS disorders. Comparable psychedelic-mechanism drug development focus.
• GH Research: Public clinical-stage company developing mebufotenin and other psychedelic-inspired therapies for treatment-resistant depression. Comparable psychedelic-mechanism approach and CNS indication focus.

Broad incumbents

• Sage Therapeutics: Public CNS-focused biopharma with FDA-approved MDD therapy (Zurzuvae). Comparable focus on CNS therapeutics and MDD as a target indication, though operating at larger scale with broader portfolio.
• Axsome Therapeutics: Public CNS therapeutics company with FDA-approved MDD therapy (Auvelity). Comparable target indication (MDD) and small-molecule CNS approach at a more advanced commercial stage.
• Janssen Pharmaceuticals (Johnson & Johnson): Large pharmaceutical company that brought Spravato (esketamine) to market for treatment-resistant depression. Comparable CNS/MDD therapeutic space and incumbent benchmark for psychedelic-adjacent regulatory approvals.

Emerging players

• Seelos Therapeutics: Small public CNS-focused biotech with pipeline assets in neurodegenerative and psychiatric indications. Comparable therapeutic area overlap (neurodegeneration, mental health) at similar early-stage scale.
• BioXcel Therapeutics: Public clinical-stage biopharma using AI-driven drug repositioning/discovery in neuroscience and immuno-oncology. Comparably sized CNS-focused emerging player with small-molecule pipeline assets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xtwitter.com/lucidbiotech
• LinkedInlinkedin.com/company/lucid-psycheceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lucid Psycheceuticals